Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Relugolix or Leuprolide for Treatment in Men with Prostate Cancer

Trial Status: active

This phase II trial compares the effect of relugolix to leuprolide for treatment in men with prostate cancer. Cessation of androgen deprivation therapy (ADT) and recovery of testosterone is associated with improved patient-reported quality of life (QOL) and may also reverse metabolic and inflammatory derangements (complications) that result as a consequence of ADT. Relugolix, a gonadotropin-releasing hormone (GnRH) antagonist, results in a faster recovery of serum testosterone concentrations upon cessation of ADT compared with GnRH agonists. Leuprolide is an active ingredient in a drug used to treat symptoms of advanced prostate cancer. It may stop the growth of prostate cancer cells that need testosterone to grow. It is a type of GnRH analog. Giving relugolix or leuprolide may be effective in treating in men with prostate cancer.